Showing results (131-140 of 207) with videos related to
Sort By:
Pageof 21
Journal of Gastroenterology and Hepatology|April 12, 2013
Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern CaliforniaRobert G Gish, Debbie Hana Yi, Steve Kane, et al.Molecular and Cellular Biology|June 1, 1993
Interactions between SH2 domains and tyrosine-phosphorylated platelet-derived growth factor beta-receptor sequences: analysis of kinetic parameters by a novel biosensor-based approachG Panayotou, G Gish, P End, et al.Pharmacoeconomics|October 27, 2007
Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis BDavid L Veenstra, Sean D Sullivan, Lauren Clarke, et al.Cell|March 12, 1993
SH2 domains recognize specific phosphopeptide sequencesZ Songyang, S E Shoelson, M Chaudhuri, et al.Journal of Viral Hepatitis|July 23, 2009
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis BR G Gish, T-T Chang, C-L Lai, et al.Journal of Medical Economics|December 9, 2025
Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United StatesRobert G Gish, Michel H Mendler, Edward A Mena, et al.Journal of Gastroenterology and Hepatology|November 22, 2011
Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to actionRobert G Gish, Tam D Bui, Chuc T K Nguyen, et al.Journal of Viral Hepatitis|December 17, 2025
Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United StatesRobert J Wong, Robert G Gish, Ira M Jacobson, et al.Journal of Viral Hepatitis|December 15, 2010
Is chronic hepatitis B being undertreated in the United States?C Cohen, S D Holmberg, B J McMahon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicinRobert G Gish, Camillo Porta, Lucian Lazar, et al.Pageof 21